GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Cash And Cash Equivalents

KAPA (Kairos Pharma) Cash And Cash Equivalents : $3.22 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Cash And Cash Equivalents?

Kairos Pharma's quarterly cash and cash equivalents declined from Mar. 2024 ($0.04 Mil) to Jun. 2024 ($0.02 Mil) but then increased from Jun. 2024 ($0.02 Mil) to Sep. 2024 ($3.22 Mil).

Kairos Pharma's annual cash and cash equivalents increased from Dec. 2021 ($0.07 Mil) to Dec. 2022 ($0.44 Mil) but then declined from Dec. 2022 ($0.44 Mil) to Dec. 2023 ($0.09 Mil).

Kairos Pharma Cash And Cash Equivalents Historical Data

The historical data trend for Kairos Pharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Cash And Cash Equivalents Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
0.01 0.07 0.44 0.09

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.09 0.04 0.02 3.22

Kairos Pharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Kairos Pharma  (AMEX:KAPA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Kairos Pharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Kairos Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Cash And Cash Equivalents
Comparable Companies
NERV AAGH BRTX BIXT SNSE AFMD BCDA NYMXF SPRB LPTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064
Website
https://kairospharma.com
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.